Navigation Links
Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, May 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the first quarter ended March 31, 2009.

"We continue to make significant progress with both of our product candidates -- Dimebon in patients with Alzheimer's and Huntington's diseases and MDV3100 in patients with prostate cancer. Having received written permission from the FDA to initiate a pivotal Phase 3 trial of MDV3100 in castration-resistant prostate cancer, we are on track to be in Phase 3 testing in all of our clinical programs this year," said David Hung, M.D., president and chief executive officer of Medivation. "We expect to achieve a significant milestone in June - completion of enrollment in our six-month, confirmatory, pivotal Phase 3 CONNECTION trial in mild-to-moderate Alzheimer's disease. And as part of our plan to support a broad and differentiated label for Dimebon in Alzheimer's disease, we are pleased to have initiated the Phase 3 CONCERT trial of Dimebon in combination with donepezil (Aricept(R)), and intend to begin two additional Phase 3 trials in moderate-to-severe Alzheimer's disease patients this year."

Recent Highlights and Accomplishments


  • Expect to complete patient enrollment in CONNECTION, a confirmatory, pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, in June.
  • Initiated the Phase 3 CONCERT trial in patients with mild-to-moderate Alzheimer's disease; the 12-month clinical trial is designed to evaluate the efficacy of Dimebon when added to ongoing treatment with donepezil (Aricept(R)), the leading Alzheimer's disease medication worldwide, and builds on data from a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated.
  • Completed a multicenter, randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety and tolerability of Dimebon given to Alzheimer's disease patients who currently are on a stable dose and regimen of memantine (Namenda(R)) or memantine plus donepezil. The study showed that these combinations were well tolerated.
  • In addition to the CONNECTION and CONCERT trials and a Phase 3 safety study already underway, we and Pfizer plan to initiate two additional Phase 3 studies in 2009 that will evaluate Dimebon in a total of approximately 1,100 patients with moderate-to-severe Alzheimer's disease.
  • Expect to initiate a Phase 3 trial this year to evaluate Dimebon's potential benefits on cognition in patients with mild-to-moderate Huntington's disease.
  • Presented posters featuring Dimebon at the 61st American Academy of Neurology Annual Meeting in Seattle on April 29 and 30, including a poster entitled "Estimating Disease-Modifying Effects Using a Staggered Start Approach and a Natural History Staggered Start (NHSS) Approach: Preliminary Results from a 12-Month Study of Dimebon and a 6-Month Open-Label Period."
  • Presented a poster at the American Geriatrics Society meeting in Chicago on May 1.


  • Received written permission from the U.S. Food and Drug Administration to initiate a pivotal Phase 3 trial of MDV3100 in castration-resistant prostate cancer in men who were previously treated with docetaxel-based chemotherapy; the primary endpoint of this randomized, placebo-controlled, double-blind, multinational trial will be overall survival.
  • Announced publication of an article in the May 8 issue of Science, presenting the discovery, novel mechanism of action and potent anti-androgen properties of MDV3100.
  • Conducted a podium presentation featuring MDV3100 at the 2009 American Urological Association Annual Meeting in Chicago on April 26.
  • Received acceptance by the American Society of Clinical Oncology (ASCO) of an abstract, entitled "Antitumor activity of MDV3100 in a Phase 1-2 study of castration-resistant prostate cancer (CRPC)," for oral presentation at the 2009 ASCO Annual Meeting on May 30 at 4:15 p.m. Eastern Time.
  • MDV3100 abstract selected by ASCO for inclusion in the Best of ASCO(R) program, an educational initiative covering highlights from the ASCO Annual Meeting to increase global access to cutting-edge science.

First Quarter 2009 Financial Results

Revenue for the first quarter of 2009 was $16.3 million, consisting of partial recognition of the non-refundable up-front payment of $225.0 million received from Pfizer in October 2008. The up-front payment was recorded as deferred revenue upon receipt and is being recognized on a straight-line basis over the estimated performance period of the Company's obligations under its collaboration agreement with Pfizer, which the Company presently expects to complete in the first quarter of 2012.

For the three months ended March 31, 2009, total operating expenses were $22.1 million, compared with total operating expenses of $15.9 million for the same period in 2008. These figures include non-cash stock-based compensation expense of $2.6 million in the quarter ended March 31, 2009, compared with $2.1 million for the same period in 2008.

Beginning October 21, 2008, Pfizer became responsible for 60 percent of all Dimebon-related development and commercialization costs in the U.S., and 100 percent of such costs outside the U.S. The parties are making quarterly true-up payments as necessary to ensure that each bears its applicable share of costs. For the first quarter of 2009, the true-up payment payable to Medivation was $5.8 million. Medivation presents these cost-sharing true-up payments in the applicable expense line of its statement of operations.

Medivation reported a net loss for the quarter ended March 31, 2009, of $5.6 million, or $0.19 per share, compared with a net loss of $15.5 million, or $0.54 per share, for the same period in 2008.

Cash, cash equivalents and short-term investments at March 31, 2009, totaled $200.7 million, compared with $221.4 million at December 31, 2008.

Conference Call Information

To participate in today's live call beginning at 4:30 p.m. Eastern Time by telephone, please call 877-681-3376 from the U.S. or +1-719-325-4757 internationally. In addition, the live conference call is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at

This press release contains forward-looking statements, including statements regarding the timing of clinical trial initiation and enrollment, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended March 31, 2009 filed today with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

                                 MEDIVATION, INC.
                      (In thousands, except per share data)

                                                       Three Months Ended
                                                            March 31,
                                                        2009            2008

    Collaboration revenue                            $16,340              $-

    Operating expenses:
       Research and development                       15,776          11,956
       Selling, General and administrative             6,305           3,953

              Total operating expenses                22,081          15,909

    Loss from operations                              (5,741)        (15,909)
    Other income (expense):
       Interest income, net                              509             382
      Other income (expense), net                         51              (1)
                Total other income (expense)             560             381
    Loss before provision for income
     taxes                                            (5,181)        (15,528)
    Provision for income taxes                           428               2
    Net loss                                         $(5,609)       $(15,530)

    Basic and diluted net loss per share              $(0.19)         $(0.54)

    Weighted average common shares used
     in the calculation of basic and
     diluted net loss per share                       30,105          28,847

                                MEDIVATION, INC.
                 (In thousands, except share and per share data)

                                                  March 31,      December 31,
                                                     2009           2008

    Current assets:
      Cash and cash equivalents                     $50,718        $71,454
      Short-term investments                        149,970        149,968
      Receivable from collaboration partner           5,766          3,522
      Prepaid expenses and other
       current assets                                 3,127          1,957
              Total current assets                  209,581        226,901

    Property and equipment, net                         801            768
    Restricted cash                                     843            843
    Intellectual property, net                           53             54
    Other non-current assets                            664            706
    Total assets                                   $211,942       $229,272


    Current liabilities:
      Accounts payable                               $5,044         $7,166
      Accrued expenses                               10,241          5,772
      Deferred revenue                               65,361         64,286
      Other current liabilities                         103             93
            Total current liabilities                80,749         77,317

    Deferred revenue, net of current                130,722        148,137
    Other non-current liabilities                       425            399
    Series A redeemable preferred stock                  11             11
            Total liabilities                       211,907        225,864

    Stockholders' equity:
      Preferred stock, $0.01 par value
       per share; 1,000,000 shares authorized;
       no shares issued and outstanding                   -              -
      Common stock, $0.01 par value per
       share;  50,000,000 shares authorized;
       issued and outstanding 30,125,556 shares
       at March 31, 2009 and 30,088,390
       at December 31, 2008                             301            301
      Additional paid-in capital                    127,800        125,074
      Accumulated other comprehensive income            203            693
      Accumulated deficit                          (128,269)      (122,660)
            Total stockholders' equity                   35          3,408

    Total liabilities and stockholders' equity     $211,942       $229,272

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... Las Vegas, NV (PRWEB) , ... November 26, 2015 , ... ... holiday shopping strategy. Many customers choose to buy during the Black Friday and ... holiday gifts. Shoppers don’t need to search the Internet high and low to find ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and ... diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians can ... from their electronic medical record (EMR) without the need for redundant patient entry ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/27/2015)... , Nov. 26, 2015 ... addition of the "2016 Global Tumor ... Country Volume and Sales Segment Forecasts, Innovative ... report to their offering. --> ... of the "2016 Global Tumor Marker ...
(Date:11/26/2015)... November 27, 2015 ... --> Medical alert ... system (PERS) market is expected ... years with APAC being the ... see a high CAGR between ...
Breaking Medicine Technology: